- All Drug Categories
- Home
- Anti-cancer Drugs
- Healthcare Products
- Medical Information
- Statement
Ibrutinib is an oral Bruton's tyrosine kinase (BTK) inhibitor widely used in the treatment of B-cell malignancies such as chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström's macroglobulinemia. Its administration is relatively simple—once daily, with or without food—but the management of missed doses and treatment interruption is directly related to efficacy and safety, and patients must master it strictly.
Take at a fixed time: It is recommended to take the drug at the same time every day to maintain stable blood drug concentrations and reduce forgetfulness.
With or without food: Food does not affect the absorption of Ibrutinib; patients may choose according to their own habits but should remain relatively consistent.
Swallow whole: Take with warm water; do not open, crush, or chew the capsules, as this may affect drug release.
Adequate water intake: Drink at least 200 mL of water when taking the drug to reduce the risk of gastrointestinal irritation.
Same-day make-up dose: If the missed dose is more than 12 hours before the next scheduled dose, take it immediately upon remembering.
Close to the next dose time: If less than 12 hours remain before the next dose, skip the missed dose and take the next dose as originally scheduled.
No double dosing: Under no circumstances should two doses be taken at once to "make up" for a missed dose.
Do not stop the drug on your own: Ibrutinib requires long-term continuous administration; stopping it without authorization may lead to disease progression or rebound.
Circumstances for physician-ordered interruption: In the event of severe adverse reactions (such as bleeding, infection, arrhythmia) or planned surgery, the physician must evaluate and decide whether to interrupt and for how long.
Resumption requires guidance: The timing and dose for restarting after interruption should be determined by the physician; patients must not resume on their own.
Monitoring after interruption: During the interruption period, closely observe changes in the condition and attend follow-up visits on time.
Ibrutinib is an oral Bruton's tyrosine kinase (BTK) inhibitor widely used in the treatment of B-cell malignancies such as chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström's macroglobulinemia. Its administration is relatively simple—once daily, with or without food—but the management of missed doses and treatment interruption is directly related to efficacy and safety, and patients must master it strictly.
Take at a fixed time: It is recommended to take the drug at the same time every day to maintain stable blood drug concentrations and reduce forgetfulness.
With or without food: Food does not affect the absorption of Ibrutinib; patients may choose according to their own habits but should remain relatively consistent.
Swallow whole: Take with warm water; do not open, crush, or chew the capsules, as this may affect drug release.
Adequate water intake: Drink at least 200 mL of water when taking the drug to reduce the risk of gastrointestinal irritation.
Same-day make-up dose: If the missed dose is more than 12 hours before the next scheduled dose, take it immediately upon remembering.
Close to the next dose time: If less than 12 hours remain before the next dose, skip the missed dose and take the next dose as originally scheduled.
No double dosing: Under no circumstances should two doses be taken at once to "make up" for a missed dose.
Do not stop the drug on your own: Ibrutinib requires long-term continuous administration; stopping it without authorization may lead to disease progression or rebound.
Circumstances for physician-ordered interruption: In the event of severe adverse reactions (such as bleeding, infection, arrhythmia) or planned surgery, the physician must evaluate and decide whether to interrupt and for how long.
Resumption requires guidance: The timing and dose for restarting after interruption should be determined by the physician; patients must not resume on their own.
Monitoring after interruption: During the interruption period, closely observe changes in the condition and attend follow-up visits on time.
Ibrutinib is an oral Bruton's tyrosine kinase (BTK) inhibitor widely used in the treatment of B-cell malignancies such as chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström's macroglobulinemia. Its administration is relatively simple—once daily, with or without food—but the management of missed doses and treatment interruption is directly related to efficacy and safety, and patients must master it strictly.
Take at a fixed time: It is recommended to take the drug at the same time every day to maintain stable blood drug concentrations and reduce forgetfulness.
With or without food: Food does not affect the absorption of Ibrutinib; patients may choose according to their own habits but should remain relatively consistent.
Swallow whole: Take with warm water; do not open, crush, or chew the capsules, as this may affect drug release.
Adequate water intake: Drink at least 200 mL of water when taking the drug to reduce the risk of gastrointestinal irritation.
Same-day make-up dose: If the missed dose is more than 12 hours before the next scheduled dose, take it immediately upon remembering.
Close to the next dose time: If less than 12 hours remain before the next dose, skip the missed dose and take the next dose as originally scheduled.
No double dosing: Under no circumstances should two doses be taken at once to "make up" for a missed dose.
Do not stop the drug on your own: Ibrutinib requires long-term continuous administration; stopping it without authorization may lead to disease progression or rebound.
Circumstances for physician-ordered interruption: In the event of severe adverse reactions (such as bleeding, infection, arrhythmia) or planned surgery, the physician must evaluate and decide whether to interrupt and for how long.
Resumption requires guidance: The timing and dose for restarting after interruption should be determined by the physician; patients must not resume on their own.
Monitoring after interruption: During the interruption period, closely observe changes in the condition and attend follow-up visits on time.
Ibrutinib is an oral Bruton's tyrosine kinase (BTK) inhibitor widely used in the treatment of B-cell malignancies such as chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström's macroglobulinemia. Its administration is relatively simple—once daily, with or without food—but the management of missed doses and treatment interruption is directly related to efficacy and safety, and patients must master it strictly.
Take at a fixed time: It is recommended to take the drug at the same time every day to maintain stable blood drug concentrations and reduce forgetfulness.
With or without food: Food does not affect the absorption of Ibrutinib; patients may choose according to their own habits but should remain relatively consistent.
Swallow whole: Take with warm water; do not open, crush, or chew the capsules, as this may affect drug release.
Adequate water intake: Drink at least 200 mL of water when taking the drug to reduce the risk of gastrointestinal irritation.
Same-day make-up dose: If the missed dose is more than 12 hours before the next scheduled dose, take it immediately upon remembering.
Close to the next dose time: If less than 12 hours remain before the next dose, skip the missed dose and take the next dose as originally scheduled.
No double dosing: Under no circumstances should two doses be taken at once to "make up" for a missed dose.
Do not stop the drug on your own: Ibrutinib requires long-term continuous administration; stopping it without authorization may lead to disease progression or rebound.
Circumstances for physician-ordered interruption: In the event of severe adverse reactions (such as bleeding, infection, arrhythmia) or planned surgery, the physician must evaluate and decide whether to interrupt and for how long.
Resumption requires guidance: The timing and dose for restarting after interruption should be determined by the physician; patients must not resume on their own.
Monitoring after interruption: During the interruption period, closely observe changes in the condition and attend follow-up visits on time.
Disclaimer：《Ibrutinib administration guidelines: once daily, management of missed and discontinued doses》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！
Full Name：Ibrutix、lbrucent、Imbruvica、Ibrutinib、伊布替尼、亿珂、依鲁替尼
Reference Price：$769.00
Prescribing Information： 依鲁替尼(Ibrutinib)是一种小分子激酶抑制剂，通过阻断B细胞受体(BCR)信号通路，抑制恶性B淋巴细胞的增殖和存活，同时调节肿瘤微环境，用于治疗多种B细胞恶性肿瘤及慢性移植物抗宿主病(cGVHD)。 一、药品名称 1、通用名：依鲁替尼(Ibrutinib) 2、...
